Insmed Incorporated (Nasdaq:INSM), a US-based global biopharmaceutical company, announced on Friday that it has completed enrolment of adult patient in its pivotal ASPEN study of brensocatib.

ASPEN is a global, randomised, double-blind, placebo-controlled Phase 3 study to assess the efficacy, safety, and tolerability of brensocatib in patients ages 12 to 85 years with non-cystic fibrosis bronchiectasis. More than 1,700 adult patients have been enrolled and randomised (1:1:1) to receive brensocatib 10mg, brensocatib 25mg, or placebo once daily for 52 weeks, followed by 4 weeks off treatment. The primary endpoint is the rate of pulmonary exacerbations over the 52-week treatment period.

Insmed anticipates reporting topline data from adults in the ASPEN trial in the second quarter of 2024.